Reported about 3 hours ago
The U.S. pharmaceutical industry is lobbying for changes to the Medicare drug price negotiation rules established under the Inflation Reduction Act, aiming to delay the eligibility timeline for price negotiations particularly for small molecule drugs. As Trump transitioning back to office, the industry seeks to engage with his team to modify these regulations, arguing that current terms could hinder innovation and drug development. The government estimates significant savings through these negotiations, but the industry is concerned about their impact on the development of cheaper oral medications.
Source: YAHOO